Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
Cameron Herberts(Natera (United States)), Alexander W. Wyatt(University of British Columbia), Arkhjamil Angeles, Steven Yip(University of Calgary), Gang Wang(Spinal Cord Injury BC), Anna Gleave(University of British Columbia), Sinja Taavitsainen(Tampere University of Applied Sciences), Elena Schönlau(University of British Columbia), Ben Tran(The Royal Melbourne Hospital), Matti Annala(Tampere University), Fred Saad(Centre Hospitalier de l’Université de Montréal), Gillian Vandekerkhove(University of British Columbia), Sebastién J. Hotte(Juravinski Cancer Centre), Andrew J. Murtha(University of British Columbia), Scott North, Martin Gleave(University of British Columbia), Matti Nykter(University of Liverpool), Simon Fu(BC Cancer Agency), Elie Ritch(University of British Columbia), Evan W. Warner(Guardant (United States)), Dong Lin(University of British Columbia), Yuzhuo Wang(BC Cancer Agency), Hui Xue, Kim N.(Asian Institute of Technology), Nayyer Iqbal(University of Saskatchewan), Kevin Beja(University of British Columbia)
Cited by 90
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k